Rationale for once-daily or twice-daily dosing of zanubrutinib in patients with mantle cell lymphoma

This report summarizes a totality-of-evidence approach supporting recommendation of a 320-mg total daily dose, either as 160-mg twice daily (BID) or 320-mg once daily (QD) for zanubrutinib in patients with mantle cell lymphoma. Data were derived from a phase 2 study in patients receiving 160-mg BID and a phase 1/2 study with similar response rates observed with 160-mg BID or 320-mg QD. Given the limited number of patients in the QD dose group, population pharmacokinetics and exposure-response analyses were employed to bridge the two regimens. The analyses showed that similar plasma exposure and BTK inhibition were achieved, and differences in trough concentration and maximum plasma concentration between the two regimens are unlikely to have a meaningful impact on efficacy and safety endpoints. The totality of data, including pharmacokinetic, pharmacodynamic, safety, efficacy, and exposure-response analyses, provided support for the recommended 320-mg total daily dose for the approved indication.

Automated summary

This report summarizes the evidence supporting the recommendation of a 320-mg total daily dose for zanubrutinib in patients with mantle cell lymphoma, with data from phase 2 and phase 1/2 studies showing similar response rates with 160-mg BID or 320-mg QD regimens. Population pharmacokinetics and exposure-response analyses bridged the two regimens, demonstrating similar plasma exposure and BTK inhibition. The totality of data supports the 320-mg total daily dose for the approved indication.